VCRE VCRE
Company Profile ↓Company Overview
VCRE (VCRE) is a publicly traded company listed on with a market capitalization of $3.33B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $3.82M (-96.5% YoY); net profit $-477.47M.
- Trailing 12 Months Year-on-year growth — revenue -96.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -96.51% |
Stock Price Performance
| 1 Year: | -27.23% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -21.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)17.11 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 27.2% below its 52-week high.
- RSI at 17 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 5.10M | 892.00K | 1.75M | - | 419.00K | 602.00K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | 5.10M | 892.00K | 1.75M | - | 419.00K | 602.00K |
| Operating Expenses | 99.19M | 92.44M | 112.92M | - | 134.13M | 124.45M |
| Operating Income | -94.09M | -91.55M | -111.17M | - | -133.71M | -123.84M |
| EBITDA | -84.07M | -85.13M | -100.86M | - | -128.56M | -107.89M |
| Interest Expense | 1.00K | 26.41M | 14.50M | - | 8.55M | 643.00K |
| Pretax Income | -84.08M | -111.53M | -115.36M | - | -137.10M | -108.53M |
| Tax Provision | 0 | 0 | 0 | - | 0 | 86.00K |
| Net Income | -84.08M | -111.53M | -115.36M | - | -137.10M | -108.62M |
| Diluted EPS | - | -0.48 | -0.49 | -0.48 | -0.54 | -0.39 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 109.35M | 3.82M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | 0 | 0 | 109.35M | 3.82M |
| Operating Expenses | - | 287.49M | 320.89M | 299.71M | 458.26M |
| Operating Income | - | -287.49M | -320.89M | -190.36M | -454.44M |
| EBITDA | - | -285.19M | -307.90M | -166.64M | -477.41M |
| Interest Expense | - | 8.00K | 2.00K | 8.00K | 60.00K |
| Pretax Income | - | -288.81M | -311.33M | -168.89M | -477.47M |
| Tax Provision | - | -384.00K | -384.00K | -256.00K | 0 |
| Net Income | - | -288.42M | -310.94M | -168.63M | -477.47M |
| Diluted EPS | - | -3.88 | -3.18 | -1.23 | -1.99 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 338.01M | 497.84M | 1.20B | 1.22B |
| Current Assets | - | 269.79M | 495.60M | 1.20B | 1.22B |
| Cash & Equivalents | - | 256.80M | 333.62M | 1.16B | 578.15M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 48.92M | 42.45M | 66.25M | 123.17M |
| Current Liabilities | - | 46.42M | 40.96M | 65.69M | 118.43M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 289.08M | 455.39M | 1.13B | 1.10B |
| Shares Outstanding | - | 84.12M | 114.83M | 234.58M | 281.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -299.92M | -249.58M | -164.95M | -375.74M |
| Investing Cash Flow | - | 74.00M | -144.46M | 149.04M | -600.51M |
| Financing Cash Flow | - | 187.04M | 470.86M | 834.06M | 430.54M |
| Capital Expenditure | - | -3.00M | - | - | - |
| Free Cash Flow | - | -302.92M | -249.58M | -164.95M | -375.74M |
| Net Change in Cash | - | -38.88M | 76.82M | 818.15M | -545.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 100.0% | 100.0% |
| Operating Margin % | - | - | - | -174.1% | -11,905.8% |
| Net Margin % | - | - | - | -154.2% | -12,509.1% |
| ROE % | - | -99.8% | -68.3% | -14.9% | -43.6% |
| ROCE % | - | -98.6% | -70.2% | -16.8% | -41.3% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VCRE
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBfSG9LLWNlT2NnRTJYb0dRN1VYbnYzN2l2UTUwZThzQzBfeUtOcm00eW42ZDNWdnRBclJPa3lJRFdMRlBfaVZhY2FkaGtScWk3?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Vicore Pharma Holding AB (publ) (VCRE) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1OUmVJSzBEck44Z3FDU1Nlb2xmWWdVLTBZcFJ6T25WNVJrbUdfRHhTaVdLRVdsWUVHZXFQcnFnT3QtUFJBdDBtbmpBX0hIcnVrTXc?oc=5" target="_blank">Vicore Pharma Holding AB (publ) (VCRE) stock price, news…
VCRE Income Statement - TradingKey
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE0yZ3dZTWh3UTFpaGRBR21hcVFFTDhYS29uMUNhUDlIT2gtblBRY0RiX213YUJMSGJWSGl2eHdOY3pCcWhmTy12Q3Y4ZGd2SFp1WktUU2NtRzl3ZWlsUU5pWHN6UFhhUFNpM2JsTW9HUHk?oc=5" target="_blank">VCRE Income Stat…
Vicore Pharma to Commence Trading in the United States on The Nasdaq Stock Market - TradingView
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQWXN6V0hOdWFmelZHNmcxc1l1Vzk0dUNZbENCQmJXdHp2cnUtSURHX19YeFBEc0NiNlZLNFoxOTd4akJFOWJ4VlM2V2MzYVZxYXVTam5VVlNkRVhLdEFzR0g5NmRLTmQxWmNsOU9Da0lRZURPVS1MRHpxS1M3cTZkRVR2RVEwcFc5Rm5sek…
Vicore Pharma Holding AB (publ) (VCRE) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9oaEFBYVdFN0xQNjZOSk1qQzJpVmxHNW5Bb2tfUUNHODlnczcwUmRrODZmRGZ0TGtWVUo4ak9xSTk0bmV6NWtiWmhMMmxtVDdfTEE?oc=5" target="_blank">Vicore Pharma Holding AB (publ) (VCRE) stock price, news…
VCRE|Vicore Pharma Holding AB ADR|Price:11.400| - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE50MHY0UnJfRHRGRUFUNlFSa2JUS01pSDFkV1RBN2VaQ3RQV081VWt5Q2ZZcUpMQ3k5VjN3M2F2TlpUSWdTQTRCbjdSNHNvazZfQnFZbzN4NUQyMk5oT2JuZXB3ajAwSkxNQlJfekRB?oc=5" target="_blank">VCRE|Vicore Pharma …
VCRE — Frequently Asked Questions
What is the current share price of VCRE?
As of 2026-08-05 17:25 PDT, VCRE trades at $11.82 on NASDAQ/NYSE. Its 52-week range is $11.03 to $16.25.
What is the market capitalisation of VCRE?
VCRE has a market capitalisation of $3.33B on NASDAQ/NYSE.
What is the P/E ratio of VCRE?
VCRE trades at a trailing price-to-earnings (P/E) ratio of -5.94. Its price-to-book (P/B) ratio is 3.04.
What is the return on equity (ROE) of VCRE?
VCRE has a return on equity (ROE) of -43.59%. Its return on capital employed (ROCE) is -41.31%.
Is VCRE a good stock to buy?
This page provides a data-driven analysis of VCRE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.